Indobufen in Secondary Prevention of Transient Ischaemic Attack

Abstract

The secondary prevention of transient ischaemic attacks was assessed in 270 patients treated orally with 100 mg indobufen given twice daily for 12 months. After 1 month's treatment, the average number and average incidence of transient ischaemic attacks were reduced significantly (P less than 0.001) and remained suppressed throughout the treatment period. Treatment was interrupted in 17 patients: in two because of side-effects (gastric disturbances); in 10 because of fatal events (six completed strokes, two myocardial infarcts and two unrelated deaths); and in five due to poor protocol compliance. Progression to reversible ischaemic neurological deficit occurred in five patients. Most side-effects were mild and transient, mainly occurring in the first month of treatment. Overall, indobufen was judged to have good efficacy and safety by both patients and physicians.

Metal‐Free K2S2O8 Mediated Synthesis of 3‐(Substituted)‐2‐Arylisoindolin‐1‐One Derivatives With Cascade C−N/C−C Bond Formations Via Radical Cyclization

“…Pagoclone (A) is a commercialized anxiolytic medication. [17] The majority of 3-substituted isoindolin-1-one compounds are identified and harvested from plants, and in order to uncover molecules with biological activity and potential for use as drugs, their lactam skeleton frequently has to be optimised and modified structurally. [18] So many 3-sustituted isoindolin-1-one skeleton units have drawn interest as a crucial intermediary in the synthesis of several valuable organic molecules and natural products.…”

“…Dopamine D 4 receptor (S)‐PD 172938 [12] pazinaclone (DN2327) [15] is a sedative, and (R)‐JM1232 [16] is an anxiolytic drug. Pagoclone (A) is a commercialized anxiolytic medication [17] …”